172 related articles for article (PubMed ID: 36409270)
1. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL.
Liao YY; Chuang YT; Lin HY; Lin NY; Hsu TW; Hsieh SC; Chen ST; Hung JS; Yang HJ; Liang JT; Huang MC; Huang J
Mol Oncol; 2023 Jan; 17(1):119-133. PubMed ID: 36409270
[TBL] [Abstract][Full Text] [Related]
2. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
3. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
4. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.
Hu Q; Tian T; Leng Y; Tang Y; Chen S; Lv Y; Liang J; Liu Y; Liu T; Shen L; Dong X
Cell Mol Biol Lett; 2022 Sep; 27(1):71. PubMed ID: 36058918
[TBL] [Abstract][Full Text] [Related]
5. Expression of GALNT2 in human extravillous trophoblasts and its suppressive role in trophoblast invasion.
Liao WC; Chen CH; Liu CH; Huang MJ; Chen CW; Hung JS; Chou CH; Chen CH; Che MI; Chang HM; Lan CT; Huang HC; Tseng GF; Shyu MK; Huang MC
Placenta; 2012 Dec; 33(12):1005-11. PubMed ID: 23117232
[TBL] [Abstract][Full Text] [Related]
6. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
7. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
Wang W; Sun R; Zeng L; Chen Y; Zhang N; Cao S; Deng S; Meng X; Yang S
Life Sci; 2021 Jul; 276():119439. PubMed ID: 33785338
[TBL] [Abstract][Full Text] [Related]
8. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
9. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer.
Mudduluru G; Vajkoczy P; Allgayer H
Mol Cancer Res; 2010 Feb; 8(2):159-69. PubMed ID: 20145042
[TBL] [Abstract][Full Text] [Related]
10. The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Hu WT; Yeh CC; Liu SY; Huang MC; Lai IR
Am J Cancer Res; 2018; 8(9):1739-1751. PubMed ID: 30323967
[TBL] [Abstract][Full Text] [Related]
11. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Sun Z; Xue H; Wei Y; Wang C; Yu R; Wang C; Wang S; Xu J; Qian M; Meng Q; Li G
Clin Sci (Lond); 2019 May; 133(10):1167-1184. PubMed ID: 31076460
[TBL] [Abstract][Full Text] [Related]
12. Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Liu SY; Shun CT; Hung KY; Juan HF; Hsu CL; Huang MC; Lai IR
Oncotarget; 2016 Mar; 7(10):11251-62. PubMed ID: 26848976
[TBL] [Abstract][Full Text] [Related]
13. O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer.
Zhou L; Wu H; Bai X; Min S; Zhang J; Li C
Pathol Oncol Res; 2022; 28():1610554. PubMed ID: 36110252
[TBL] [Abstract][Full Text] [Related]
14. Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Zilmer M; Edmondson AC; Khetarpal SA; Alesi V; Zaki MS; Rostasy K; Madsen CG; Lepri FR; Sinibaldi L; Cusmai R; Novelli A; Issa MY; Fenger CD; Abou Jamra R; Reutter H; Briuglia S; Agolini E; Hansen L; Petäjä-Repo UE; Hintze J; Raymond KM; Liedtke K; Stanley V; Musaev D; Gleeson JG; Vitali C; O'Brien WT; Gardella E; Rubboli G; Rader DJ; Schjoldager KT; Møller RS
Brain; 2020 Apr; 143(4):1114-1126. PubMed ID: 32293671
[TBL] [Abstract][Full Text] [Related]
15. GALNT2 targeted by miR-139-5p promotes proliferation of clear cell renal cell carcinoma via inhibition of LATS2 activation.
Yi H; Liu L; Zhang J; Guo K; Cao Y; Sun P; Wang H
Discov Oncol; 2024 Mar; 15(1):73. PubMed ID: 38478152
[TBL] [Abstract][Full Text] [Related]
16. A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis.
Verzijl CRC; Oldoni F; Loaiza N; Wolters JC; Rimbert A; Tian E; Yang W; Struik D; Smit M; Kloosterhuis NJ; Fernandez AJ; Samara NL; Ten Hagen KG; Dalal K; Chernish A; McCluggage P; Tabak LA; Jonker JW; Kuivenhoven JA
Mol Metab; 2022 Jun; 60():101472. PubMed ID: 35304331
[TBL] [Abstract][Full Text] [Related]
17. GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
Beaman EM; Carter DRF; Brooks SA
Glycobiology; 2022 Jun; 32(7):556-579. PubMed ID: 35312770
[TBL] [Abstract][Full Text] [Related]
18. Polypeptide
Kato K; Hansen L; Clausen H
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576978
[TBL] [Abstract][Full Text] [Related]
19. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
Yu Y; Wang Z; Zheng Q; Li J
Gene; 2021 Jul; 790():145689. PubMed ID: 33964375
[TBL] [Abstract][Full Text] [Related]
20. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2.
Hung JS; Huang J; Lin YC; Huang MJ; Lee PH; Lai HS; Liang JT; Huang MC
Oncotarget; 2014 Apr; 5(8):2096-106. PubMed ID: 24758762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
